Uploaded July 2016 | Updated September 2026, 2 weeks ago
Phil Schein, M.D., CASIS Board of Director, adresses Genes in Space 2016 Finalists at ISS Research and Development Conference 2016.
Dr. Schein has held major positions in the field of Medical Oncology, serving as President of the American Society of Clinical Oncology and he has chaired the Food and Drug Administration's Oncologic Drugs Advisory Committee. He has served as a member of the Board of Directors on the American Board of Internal Medicine, where he chaired the Medical Oncology Committee. He was appointed by President Clinton to the National Cancer Advisory Board. Dr. Schein also served as co-Chairman of the Gastrointestinal Cancer Tumor Study Group and was a founding member of the Japan-American, French-American Agreement and Pan American Health Organization-US Agreements on Cancer Research.
Dr. Philip Schein is widely regarded as a leading international authority in the treatment of cancer, authoring over 350 articles and texts relating to basic and clinical cancer research and drug development, and has been awarded 11 patents. He is a recipient of numerous scientific and medical awards including the Harvey W. Wiley Medal from the FDA and the Wainwright Award for Excellence in Medical Education and serves on numerous biotechnology/pharmaceutical scientific advisory boards.
Phil Schein, M.D., CASIS Board of Director, adresses Genes in Space 2016 Finalists at ISS Research and Development Conference 2016.
Dr. Schein has held major positions in the field of Medical Oncology, serving as President of the American Society of Clinical Oncology and he has chaired the Food and Drug Administration's Oncologic Drugs Advisory Committee. He has served as a member of the Board of Directors on the American Board of Internal Medicine, where he chaired the Medical Oncology Committee. He was appointed by President Clinton to the National Cancer Advisory Board. Dr. Schein also served as co-Chairman of the Gastrointestinal Cancer Tumor Study Group and was a founding member of the Japan-American, French-American Agreement and Pan American Health Organization-US Agreements on Cancer Research.
Dr. Philip Schein is widely regarded as a leading international authority in the treatment of cancer, authoring over 350 articles and texts relating to basic and clinical cancer research and drug development, and has been awarded 11 patents. He is a recipient of numerous scientific and medical awards including the Harvey W. Wiley Medal from the FDA and the Wainwright Award for Excellence in Medical Education and serves on numerous biotechnology/pharmaceutical scientific advisory boards.
